Prostaglandin E1 (PGE1) is a medication used to manage erectile dysfunction and ductus arteriosus in neonates. It is a smooth muscle relaxant and vasodilator. This article outlines the indications, mechanism of action, and contraindications of taking alprostadil as a valuable agent in treating erectile dysfunction and neonatal congenital heart defects. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the healthcare team in the treatment of patients with the conditions as mentioned above.

**Objectives:**
- Identify the mechanism of action of PGE1 (alprostadil). 
- Describe the adverse effects of PGE1 (alprostadil). 
- Review the toxicity of PGE1 (alprostadil). 
- Outline interprofessional team strategies for improving care coordination and communication to improve PGE1 (alprostadil) therapy and improve outcomes.